Related Experiment Video
Updated: May 15, 2026
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease
Yoshihiro Inamoto1, Barry E Storer, Stephanie J Lee
1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. yinamoto@fhcrc.org
Abstract:
This study attempted to characterize causes of treatment failure, identify associated prognostic factors, and develop shorter-term end points for trials testing investigational products or regimens for second-line systemic treatment of chronic graft-versus-host disease (GVHD). The study cohort (312 patients) received second-line systemic treatment of chronic GVHD. The primary end point was failure-free survival (FFS) defined by the absence of third-line treatment, nonrelapse mortality, and recurrent malignancy during second-line treatment. Treatment change was the major cause of treatment failure. FFS was 56% at 6 months after second-line treatment. Lower steroid doses at 6 months correlated with subsequent withdrawal of immunosuppressive treatment. Multivariate analysis showed that high-risk disease at transplantation, lower gastrointestinal involvement at second-line treatment, and severe NIH global score at second-line treatment were associated with increased risks of treatment failure. These three factors were used to define risk groups, and success rates at 6 months were calculated for each risk group either without or with various steroid dose limits at 6 months as an additional criterion of success. These success rates could be used as the basis for a clinically relevant and efficient shorter-term end point in clinical studies that evaluate agents for second-line systemic treatment of chronic GVHD.
Insights
Treatment changes frequently cause failure in chronic graft-versus-host disease (GVHD) treatment. Researchers identified key factors like disease risk and GI involvement to predict treatment failure and develop shorter endpoints for clinical trials.
Area of Science:
- Hematology
- Immunology
- Clinical Trials
Background:
- Chronic graft-versus-host disease (GVHD) is a significant complication following allogeneic stem cell transplantation.
- Optimizing second-line systemic treatment strategies and endpoints is crucial for improving patient outcomes.
Purpose of the Study:
- To identify causes of treatment failure in second-line chronic GVHD therapy.
- To determine prognostic factors associated with treatment failure.
- To develop shorter-term endpoints for clinical trials in chronic GVHD.
Main Methods:
- Retrospective analysis of 312 patients receiving second-line systemic treatment for chronic GVHD.
- Primary endpoint: failure-free survival (FFS), defined by lack of third-line treatment, non-relapse mortality, or recurrent malignancy.
- Multivariate analysis to identify prognostic factors and define risk groups.
Main Results:
- Treatment change was the primary reason for treatment failure.
- Failure-free survival at 6 months was 56%.
- High-risk disease at transplantation, lower GI involvement, and severe NIH global score were associated with increased treatment failure risk.
Conclusions:
- Treatment failure in chronic GVHD is often due to the need for subsequent therapies.
- Identified prognostic factors (disease risk, GI involvement, NIH score) can stratify patients.
- Developed success rates based on risk groups and steroid dose criteria can serve as efficient shorter-term endpoints for clinical studies.
Related Concept Videos
01:40Cell-mediated Immune Responses
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:56Treatment Resistant Cancers